The Safety of Infliximab Infusions in the Community Setting
BACKGROUND: Tumour necrosis factor-alpha (TNFα) has an important role in the pathogenesis of inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis and psoriasis. Infliximab, a chimeric anti-TNFα monoclonal antibody, has been shown to reduce the severity of symptom...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2010-01-01
|
| Series: | Canadian Journal of Gastroenterology |
| Online Access: | http://dx.doi.org/10.1155/2010/138456 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832562475839520768 |
|---|---|
| author | James Ducharme Cindy Pelletier Ramesh Zacharias |
| author_facet | James Ducharme Cindy Pelletier Ramesh Zacharias |
| author_sort | James Ducharme |
| collection | DOAJ |
| description | BACKGROUND: Tumour necrosis factor-alpha (TNFα) has an important role in the pathogenesis of inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis and psoriasis. Infliximab, a chimeric anti-TNFα monoclonal antibody, has been shown to reduce the severity of symptoms or induces remission of active disease. Infusions have generally been limited to the hospital setting due to cost and concerns for patient safety. Studies defining its efficacy and safety have, therefore, originated almost exclusively from hospital settings. |
| format | Article |
| id | doaj-art-74e485461a6c433181448c5126763538 |
| institution | Kabale University |
| issn | 0835-7900 |
| language | English |
| publishDate | 2010-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology |
| spelling | doaj-art-74e485461a6c433181448c51267635382025-02-03T01:22:34ZengWileyCanadian Journal of Gastroenterology0835-79002010-01-0124530731110.1155/2010/138456The Safety of Infliximab Infusions in the Community SettingJames Ducharme0Cindy Pelletier1Ramesh Zacharias2Department of Medicine, McMaster University, Hamilton, CanadaAIM Health Group, CanadaCentres for Pain Management, Mississauga, Ontario, CanadaBACKGROUND: Tumour necrosis factor-alpha (TNFα) has an important role in the pathogenesis of inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis and psoriasis. Infliximab, a chimeric anti-TNFα monoclonal antibody, has been shown to reduce the severity of symptoms or induces remission of active disease. Infusions have generally been limited to the hospital setting due to cost and concerns for patient safety. Studies defining its efficacy and safety have, therefore, originated almost exclusively from hospital settings.http://dx.doi.org/10.1155/2010/138456 |
| spellingShingle | James Ducharme Cindy Pelletier Ramesh Zacharias The Safety of Infliximab Infusions in the Community Setting Canadian Journal of Gastroenterology |
| title | The Safety of Infliximab Infusions in the Community Setting |
| title_full | The Safety of Infliximab Infusions in the Community Setting |
| title_fullStr | The Safety of Infliximab Infusions in the Community Setting |
| title_full_unstemmed | The Safety of Infliximab Infusions in the Community Setting |
| title_short | The Safety of Infliximab Infusions in the Community Setting |
| title_sort | safety of infliximab infusions in the community setting |
| url | http://dx.doi.org/10.1155/2010/138456 |
| work_keys_str_mv | AT jamesducharme thesafetyofinfliximabinfusionsinthecommunitysetting AT cindypelletier thesafetyofinfliximabinfusionsinthecommunitysetting AT rameshzacharias thesafetyofinfliximabinfusionsinthecommunitysetting AT jamesducharme safetyofinfliximabinfusionsinthecommunitysetting AT cindypelletier safetyofinfliximabinfusionsinthecommunitysetting AT rameshzacharias safetyofinfliximabinfusionsinthecommunitysetting |